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Abstract
Objective—Treatment guidelines suggest distinctive medication strategies for first episode and
multi-episode patients with schizophrenia. How much community clinicians adjust their usual
treatment regimens for first episode patients is unknown. We examined prescription patterns and
factors associated with prescription choice within a national cohort of early phase patients.

Author Manuscript

Method—Study entry prescription data (before any influence on treatment by study procedures)
were obtained from 404 participants in the RAISE-ETP study, a US nationwide effectiveness
study conducted at 34 community treatment centers in 21 states for patients with first episode
schizophrenia-spectrum disorders. Subjects had been treated with antipsychotics for 6 months or
less at study entry.
Results—We identified 159 subjects (39.4% of the sample) who might benefit from changes in
their psychotropic prescriptions. Of these 159 subjects, 8.8% were prescribed recommended
antipsychotics at higher than recommended doses, 32.1% were prescribed olanzapine (often at
high doses), 23.3% more than one antipsychotic, 36.5% an antipsychotic but also an
antidepressant without a clear indication, 10.1% psychotropic medications without an
antipsychotic and 1.2% stimulants.

Author Manuscript

Multivariate analyses found evidence for sex, age and insurance status effects on medication
prescription. Racial and ethnic effects consistent with effects found in prior multi-episode studies
were found in univariate analyses. There were some regional variation in prescription practices;
when present, regional patterns varied across prescribing practices. Diagnosis had limited, and
inconsistent, effects.
Conclusions—Besides prescriber education, policy makers may need to consider not only
patient factors but also service delivery factors in efforts to improve first episode prescription
practices.
Clinical Trials registration—NCT01321177: An Integrated Program for the Treatment of First
Episode of Psychosis (RAISE ETP), http://www.clinicaltrials.gov/ct2/show/NCT01321177
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Introduction
Research supports different medication treatment approaches for first episode and multiepisode schizophrenia (reviewed (1)) and recent schizophrenia treatment practice guidelines
(e.g (2–6)) include specific first episode recommendations. Since the incidence of
schizophrenia is low (7), most clinicians’ experience outside of specialty centers is heavily
weighted towards the treatment of multi-episode patients. How much community clinicians
adjust their treatment regimens for first episode patients is unknown.

Author Manuscript

The Early Treatment Program (ETP) study, a nationwide comparative effectiveness trial that
is part of the National Institute of Mental Health Recovery After an Initial Schizophrenia
Episode (RAISE) initiative, provided the basis for the first national report of U.S.
community mental health center medication treatments for the crucial early phase of
schizophrenia. We addressed two questions: what are the medication treatments currently
used in community settings and are there factors associated with choice of medication
strategies.

Method
Study overview
RAISE-ETP compares NAVIGATE, a coordinated specialty care treatment program for first
episode psychosis that includes medical management guided by a decision support system,
individual therapy, family psychoeducation, and supported employment and education, and
Community Care, treatment determined by clinician choice. RAISE-ETP was conducted
under the guidance of the respective institutional review boards for the coordinating center
and the sites.

Author Manuscript
Author Manuscript

The design prioritized enhancing generalizability of findings to community settings.
Inclusion/exclusion criteria were chosen to allow broad inclusion of different patient
subgroups. Inclusion criteria were: age 15 to 40 years; diagnosis of schizophrenia,
schizophreniform disorder, schizoaffective disorder, psychosis NOS or brief psychotic
disorder; beginning first treatment for psychosis (defined as having taken antipsychotic
medications cumulatively for 6 months or less) and ability to participate in research
assessments in English. Exclusion criteria were: had clearly experienced more than one
discrete psychotic episode; diagnosis of bipolar disorder, psychotic depression, substanceinduced psychotic disorder or current psychotic disorder due to a general medical condition;
presence of current neurological disorders that would affect diagnosis or prognosis;
clinically significant head trauma or other serious medical conditions that would
significantly impair assessment, functioning or treatment. All subjects provided written
informed consent (or written assent for those under age 18 along with parent’s/guardian’s
written consent).
We employed site randomization to facilitate participation by sites without previous research
experience, to eliminate potential treatment strategy “spillover” effects and to enhance study
acceptability by patients who would not need to agree to individual randomization. Thirtyfour sites in 21 states were selected after a national search. All were community treatment
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centers with no preexisting first episode program. Sites were intentionally located in diverse
settings, ranging from large urban to rural settings. Seventeen sites were randomized to
deliver NAVIGATE treatment and 17 to Community Care.
RAISE-ETP data specific to this report were collected between July 2010 and July 2012.

Author Manuscript

RAISE-ETP assessments pertinent to this report: Site staff obtained medication data using
all available sources of information including direct interview with subjects and their
families (if available) and record review. Medication history collection was a priority in
order to establish study eligibility that specified maximum antipsychotic treatment duration.
We present data on psychotropic medications being prescribed (even if not actually taken) to
subjects at study entry and before any influence on treatment by study guidelines or
procedures. Diagnoses were determined using the Structured Clinical Interview for Axis 1
DSM-IV Disorders Patient Edition (SCID) (8) administered by masked remote assessors via
live, two-way video. Information sources were the subjects and a structured summary of
subject symptoms and treatment history provided to the assessor prior to the SCID
interview. Tobacco smoking status was assessed with the Fagerstrom (9) questionnaire. Data
about recent alcohol and substance use was obtained by clinic staff using record review and
direct interview of patients and their families (if available).
Statistical analyses

Author Manuscript

Prescribing patterns were characterized using standard descriptive methods (e.g.
percentages). Potential correlates for the analyses of prescribing patterns were chosen based
on the following. Sex (10), racial background (11–13) and ethnicity (14) influence
antipsychotic response or prescription patterns with multi-episode patients. Cigarette
smoking decreases blood levels of some psychotropics (15). Age was included because
some agents have adolescent indications. Prior depressive or anxiety symptoms should
influence antidepressant prescription. Prescription may differ among the various
schizophrenia-spectrum disorders or by the presence of concurrent substance use. Insurance
status influences access to particular medications and also treatment settings in the U.S. Our
data from 21 states allowed us to examine regional variations in prescription. We examined
these factors in relation to nine key prescription practices: antipsychotic prescription,
prescription of more than one antipsychotic, long acting injectable antipsychotic
prescription, first generation antipsychotic prescription, risperidone prescription and dose,
olanzapine prescription and dose and antidepressant prescription.

Author Manuscript

We adopted a Bayesian perspective for the correlates analyses. As an aid to readers
unfamiliar with Bayesian analyses, we review some features of Bayesian analyses. Bayesian
analyses do not require correction for multiple comparisons (16). Bayesian credible intervals
(CrIs) are similar to confidence intervals (CI) in classical analyses, but in the Bayesian
framework, the interval contains the true population parameter. Bayesian analyses do not
generate p-values. Instead, the posterior probability of being a risk factor (PPRF), also
sometimes referred to as selected %, is the probability that a variable is associated with an
outcome. The larger the PPRF, the stronger the evidence for an association. We present
PPRF evidence classifications adapted from (17,18): <50% lacking evidence, 50–75% some
evidence, 75–95% positive evidence, 95–99% strong evidence and >99% very strong
Am J Psychiatry. Author manuscript; available in PMC 2015 March 13.
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evidence for an association with outcomes. Studies (18) comparing results from classical
and Bayesian analyses provide additional context for PPRF interpretation. These studies
show that variables that are not significant in classical analyses have Bayesian PPRFs of less
(often much less) than 50%.

Author Manuscript

For all analyses, a weakly informative prior distribution was constructed by first scaling all
non-binary variables to have mean 0 and standard deviation 0.5, and then placing an
independent distribution from the Student t prior family (specifically, a Cauchy distribution
centered at zero and 2.5 scale) on the coefficients (19). This prior has the advantage of
always giving solutions even when there is complete separation in the logistic regression
(20,21). Univariate analysis was done using the bayesglm function in the arm package in R;
sim function was used to obtain simulates of the posterior distribution of each coefficient in
the general linear model, and 95% Crls were obtained based on the 2.5th and 97.5th
percentiles of the posterior distribution. Multivariate analyses employed Bayesian model
averaging (BMA), a Bayesian solution to the problem of inference in the presence of
multiple competing models (18). The bic.glm function from R package BMA was primarily
used for these analyses.

Results
Subjects

Author Manuscript

The CONSORT diagram Supplemental Figure 1 presents the enrollment flow. The sample
included 404 subjects. Community centers normally do not do outreach; new patients arrive
through referral from inpatient units, other clinicians or self-referral. This pattern mostly
held for the study; 335 (83%) subjects came from these sources and only 88 (17%) from
outreach activities (e.g. educating the professional community about RAISE-ETP;
educational efforts with potential patients and their families through articles in the local
press, information booths at community events). As shown in Table 1, most subjects had a
psychiatric hospitalization before study entry. Subjects were mostly young, male and from
diverse racial backgrounds. Approximately half met DSM-IV criteria for schizophrenia; the
next most common diagnoses were schizophreniform disorder and schizoaffective disorder.
Consistent with early phase illness, mean cumulative lifetime antipsychotic treatment was
only 46.7 (95% CI: 42.2, 51.2) days.
The frequency of prescription of major medication classes is presented in Table 2
Most subjects were prescribed antipsychotics and approximately a third of subjects were
prescribed antidepressants.

Author Manuscript

Subjects not prescribed antipsychotic medications at study entry
All subjects had a psychotic disorder for which antipsychotic treatment is indicated. Fiftyone (12.6%) subjects were not prescribed any psychotropic medications at study entry.
Twenty-four (47.1%) of these had had a psychiatric inpatient admission and 16 (31.4%) had
taken antipsychotics in the past. Sixteen subjects were prescribed psychotropic medications
but not antipsychotics. Fourteen of these were prescribed antidepressants, 1 clonazepam and
1 clonidine.

Am J Psychiatry. Author manuscript; available in PMC 2015 March 13.
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Of the 337 subjects prescribed an antipsychotic, only 40 (11.9%) were prescribed a first
generation agent, including subjects prescribed both a first and a second generation
antipsychotic. Long acting injectable antipsychotics were prescribed for 32 (9.5%) of the
337 subjects who were prescribed antipsychotics. Frequency of long acting injectable
prescription was: paliperidone palmitate 17 (53.1% of long acting prescriptions); 11 (34.4%)
haloperidol decanoate; 3 (9.4%) risperidone microspheres and 1 (3.1%) for fluphenazine
decanoate.
Antipsychotic monotherapy was by far the most common pattern. Three hundred (89.0%) of
the 337 subjects prescribed antipsychotics were prescribed only one antipsychotic (either in
single or multiple formulations), 35 (10.4%) were prescribed 2 different antipsychotics and
2 (0.6%) were prescribed 3 different antipsychotics.

Author Manuscript

Prescriptions for antipsychotic monotherapy—As shown in Table 3, risperidone
accounted for approximately one-third of the 300 prescriptions for antipsychotic
monotherapy. The next most commonly prescribed antipsychotic was olanzapine (17.0% of
prescriptions) followed by aripiprazole, paliperidone and quetiapine each accounting for
around 10% of prescriptions.

Author Manuscript

First episode schizophrenia treatment guidelines emphasize using low-dose strategies. As
shown in Table 3, relatively few subjects were prescribed antipsychotic doses higher than
the suggested 2009 PORT (4) upper dosing limit for multi-episode patients. High dose
strategies were found for only certain medications, notably olanzapine. 44.9% of olanzapine
prescriptions were above specific 2009 PORT guidelines (4) for first episode treatment
compared with only 7.8% of risperidone prescriptions.
Prescriptions for two or more antipsychotics—Prescriptions for multiple
antipsychotics included combinations of 13 different antipsychotics. The most commonly
prescribed agents were: risperidone prescribed to 16 (43.2%) of the 37 subjects prescribed
multiple agents; quetiapine prescribed to 13 (35.1%) subjects; olanzapine prescribed to 10
(27.0%); aripiprazole to 9 (24.3%) and haloperidol to 8 (21.6%).

Author Manuscript

Medications for motor side effects—We lack data on perceived indications for
prescriptions but anti-cholinergic medications and beta blockers are usually prescribed for
motor side effects in patients taking antipsychotics. 71 (21.1%) of the 337 subjects
prescribed an antipsychotic were concurrently prescribed an anti-cholinergic medication and
7 (2.1%) a beta blocker. Anti-anxiety agents can be prescribed for motor side effects and/or
for anxiety. Thirty-nine (11.6%) of the 337 were prescribed an anti-anxiety agent.
Antidepressants prescribed with antipsychotics—One hundred fifteen subjects
were prescribed both an antidepressant and an antipsychotic. Only 57 (49.6%) of the 115
had any SCID interview documentation of lifetime depression (i.e. major depression,
depressive disorder NOS, schizoaffective disorder, depressive type) or anxiety (i.e. panic
disorder, social phobias, obsessive-compulsive disorder, post traumatic stress disorder,
generalized anxiety disorder, anxiety due to a medical condition, anxiety disorder NOS) that
Am J Psychiatry. Author manuscript; available in PMC 2015 March 13.
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might broadly be considered justification for antidepressant treatment. Although not
recommended by treatment guidelines, antidepressants are sometimes prescribed for
negative symptoms. However, only 6 (10.3%) of the remaining 58 subjects prescribed
antidepressants had any prominent negative symptoms by SCID interview.
Factors associated with prescribing patterns

Author Manuscript
Author Manuscript
Author Manuscript

These analyses are summarized in main text Figure 1 and 2 and presented in detail in
Supplemental Materials Tables 1 and 2. Antipsychotic prescription. Univariate but not
multivariate analyses (all PPRFs <21.2%; all lacking evidence) suggested that women and
subjects with public versus private insurance were less likely to receive an antipsychotic
while those with schizophreniform versus schizophrenia or schizoaffective disorder were
more likely to receive an antipsychotic prescription. Prescriptions for two or more
antipsychotics were more likely for subjects at southern versus Midwestern sites in
univariate but not multivariate analyses (PPRF=4.6%; lacking evidence). In multivariate
analyses subjects with private insurance were less likely to be prescribed more than one
antipsychotic than either subjects with public (PPRF=52.9%; some evidence) or no
insurance (PPRF=51.9%; some evidence). Long acting injectable prescription was more
frequent for women and subjects at Midwestern versus western sites based upon univariate
but not multivariate analyses (PPRF=40.2% and 20.9%, respectively; both lacking
evidence). First generation antipsychotic prescription. Multivariate analyses showed that
first generation antipsychotic prescription was more common among the uninsured versus
those with private (PPRF=96.2%; strong evidence) or public insurance (PPRF=56.4%; some
evidence); African Americans were more likely than Caucasians to be prescribed first
generation antipsychotics based upon univariate but not multivariate analyses
(PPRF=23.1%; lacking evidence). Risperidone prescription. Multivariate analyses revealed
that younger subjects (PPRF=66.4%; some evidence) and univariate analyses only that
Hispanics (PPRF=17.5%; lacking evidence) and other racial groups (PPRF=17.5%; lacking
evidence) versus Caucasians were more likely to be prescribed risperidone. Risperidone
dose. Women received lower risperidone doses than men (PPRF=52.2%; some evidence).
Univarite but not multivariate analyses (all PPRFs <17%; all lacking evidence) showed that
subjects with psychosis NOS or schizoaffective disorder versus those with schizophrenia as
well as those with public versus no insurance were prescribed lower risperidone doses.
Olanzapine prescription in univariate but not multivariate analyses (all PPRFs <24%; all
lacking evidence) was more likely among subjects at western versus southern sites and
among those with schizophrenifrom disorder versus psychosis NOS or schizophrenia.
Olanzapine dose was lower among women than men and for those with schizoaffective
disorder versus psychosis NOS based upon univariate but not multivariate analyses
(PPRFs=47.7% and 9.7%, respectively; all lacking evidence). Antidepressant prescription
was more likely among women (PPRF=83.5%; positive evidence) and those with depression
or anxiety symptoms (PPRF=87.1%; positive evidence); older subjects and those with
schizoaffective disorder versus psychosis NOS were more likely to receive antidepressants
based upon univariate analyses only (PPRF=23.8% and 1.6%, respectively; all lacking
evidence).
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These analyses excluded subjects not being prescribed psychotropic medications at baseline
as some would not be expected to have prescriptions (e.g. someone initiating psychiatric
treatment at study entry). One hundred fifty-nine subjects (39.4% of the entire sample) met
criterion for potential benefit. Of these, 14 (8.8%) were prescribed recommended
antipsychotics at higher than recommended doses, 51 (32.1%) were prescribed olanzapine
(often at high doses), 37 (23.3%) more than one antipsychotic, 58 (36.5%) an antipsychotic
but also an antidepressant without a clear indication, 16 (10.1%) psychotropic medications
without an antipsychotic and 5 (1.2%) stimulants.

Discussion
Author Manuscript

This is the first report of psychotropic medication treatment of people with first episode
schizophrenia-spectrum disorders in US community mental health settings. The Tiihonon
national Finnish discharge registery study (22) provides an international comparison. Both
studies found similar prescription rates for long acting injectables and for multiple
antipsychotics. Risperidone followed by olanzapine were the most commonly used oral
antipsychotics in both countries. Clozapine use was much higher in Finland. This may
reflect different treatment practices or the possibility that more of the Finnish subjects failed
to respond to other antipsychotics during outpatient treatment before cohort identification
based upon their first hospitalization.

Author Manuscript
Author Manuscript

Practice guidelines (e.g. (2–6)) with specific first-episode recommendations and firstepisode research data support 1) the need for antipsychotic treatment, 2) using low
antipsychotic dosing and 3) the need to minimize side effects, especially metabolic ones,
during early phase treatment. Did community clinicians follow these core principles? The
need for antipsychotic treatment was widely recognized. Only 16 subjects were not being
prescribed antipsychotics who clearly had been evaluated for psychiatric problems as
evidenced by the prescription for a psychotropic agent. Another 35 subjects were not
prescribed any psychotropics; how many had recently seen a prescriber who did not
recognize a need for psychotropic agents is unknown. Antipsychotic prescriptions were
mostly concordant with recommendations. An exception was the relatively common use
(17.0% of antipsychotic prescriptions) of olanzapine. Due to its more frequent adverse
metabolic side effects (23), especially with first-episode patients (24), PORT guidelines
recommend that olanzapine not be used for first-episode treatment. Strikingly, olanzapine
compared with other antipsychotics was much more frequently prescribed at higher than
recommended doses. We considered the possibility that olanzapine was prescribed for
subjects who had not improved with other antipsychotics but the data do not support this.
The mean days of antipsychotic treatment for subjects prescribed olanzapine (56.2 (95% CI:
45.7, 66.7)) was similar to that for other antipsychotics (e.g. 57.8 (95% CI: 44.3, 71.3) for
paliperidone). Regarding minimizing side effects, this requires optimizing all medications,
not just antipsychotics. Of note, antidepressants were prescribed for around a third of
subjects but only around half of these subjects had clear symptom indications for
antidepressants.
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Our univariate analyses identified specific factors associated with particular prescription
practices. Prescription maybe influenced by several factors. People designing practice
improvement efforts may wish to focus upon factors identified by the multivariate analyses
due to these being less biased when confounding factors are present. Both analysis types are
informative in different contexts and we include both in our discussion. Demographic: As
with multi-episode subjects (10), women in our sample received lower antipsychotic doses.
They were also more likely to be prescribed a long acting injectable antipsychotic
(univariate only) and, even controlling for depressive and anxiety symptoms, an
antidepressant. In multi-episode studies African Americans are more likely to be prescribed
a first generation antipsychotic (12,13) and Hispanics risperidone (25); our univariate results
suggest that these patterns may also apply to first-episode treatment. Younger subjects were
more likely to be prescribed risperidone, possibly because of its FDA adolescent treatment
indication. Service delivery: We found some univariate regional differences in prescription
practices; the regions that differed varied across prescription practices with no region
consistently having different practices from the other regions. Insurance status effects were
highly consistent. Private insurance was associated with better medication prescription:
increased likelihood of antipsychotic prescription and less likelihood of receiving 2 or more
antipsychotics or receiving a first generation antipsychotic, a medication choice discouraged
by some (e.g. (3)) but not all (e.g. (4)) first-episode guidelines. Diagnosis: Diagnosis had no
effect on prescription of more than 1 antipsychotic or prescription of long acting injectables,
first generation antipsychotics or risperidone. The univariate association between
schizoaffective diagnoses and antidepressant prescription is consistent with the mood
symptoms required for the diagnosis; the basis for the univariate association between
schizophreniform disorder and olanzapine prescription is unclear. Diagnostic associations
were not consistent across analyses of risperidone and olanzapine dosing. Smoking and
substance use was not associated with risperidone or olanzapine dosing.

Author Manuscript

Our data have limitations. Our sample may not be as generalizable as a true epidemiological
sample despite being recruited from 34 sites in 21 states. Second, most subjects’
prescriptions were made at another facility, usually an inpatient unit, prior to referral to our
study community centers. Thus, we lack data on the prescribing clinicians’ decision
processes, their perceived indications for prescriptions and of the effects of patient
preferences. Third, our sample’s mean total lifetime antipsychotic prescription was only
46.7 days. For most subjects, past treatment response should not have substantially
influenced medication selection but some subjects may have had enough treatment to
document unusual responses to medication leading to treatment not conforming to
guidelines. Fourth, our large number of sites prevented including individual sites in our
analyses. Grouping sites into geographic regions provided a means to examine uniformity of
prescribing patterns nationally, but cannot provide data on individual site practices.
Despite these limitations, our data have health policy implications. The marked use of
second over first generation antipsychotics in our study may be warranted by evidence of
better efficacy (26) and relapse prevention (27) and less motor side effects (26) with second
generation antipsychotics with early phase patients. However, the marked metabolic effects
of some second generation antipsychotics with early phase patients (28–32) suggests that
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efforts (e.g. (33)) to increase adherence with recommended physical health monitoring of
first-episode patients should be strongly encouraged.
Although each questionable medication practice we identified affected only between 1.2%
to 14.4% of subjects, cumulatively 39.4% of subjects might have benefited from
psychotropic prescriptions changes. Primary immediate targets for improving first-episode
community treatment are discouraging use of two or more antipsychotics and the
prescription of, and high dose of, olanzapine. Besides educational efforts to prescribers,
changes in reimbursement models or care delivery may need to be considered to facilitate
evidence-based treatment during the crucial early phase of schizophrenia. Subjects with
private insurance had strikingly lower rates of prescription of two or more antipsychotics
than patients with public or no insurance.

Author Manuscript

A large number of our subjects received antidepressants without clear indications for their
use. Either prescribers responded to symptoms not detected by our research interviews or
they interpreted schizophrenia symptoms as mood or anxiety symptoms. If the latter is true,
training to improve clinicians’ ability to diagnose schizophrenia-spectrum disorders as
distinct from mood or anxiety disorders in women would be warranted given our finding
that women were more likely to be prescribed antidepressants independent of symptom
indications.
Better medication treatment of the initial illness episode raises the possibility of better acute
and long-term outcomes. An important first-episode research question is whether promoting
more evidence-based care does indeed improve outcomes and, if it does, what level of
adherence to evidence-based practice is required.
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Supplementary Material
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Figure 1. Factors Associated with Prescription Patterns Log Odds Ratios and 95% Credible
Intervals

Author Manuscript
Author Manuscript

Odds ratios in aqua are from multivariate analyses with selected % of 50% or greater but
less than 75% (some evidence of association)
Odds ratios in green are from multivariate analyses with selected % of 75% or greater but
less than 95% (positive evidence of association)
Odds ratios in red are from multivariate analyses with selected % of 95% or greater but less
than 99% (strong evidence of association)
Antipsychotic prescription = prescription of one or more antipsychotics versus no
antipsychotic prescribed
2 or more antipsychotics = prescription for 2 or more antipsychotics among subjects
prescribed antipsychotics. Multiple formulations of the same antipsychotic were counted as
a single antipsychotic.
Long acting antipsychotic = prescription for long acting antipsychotic or a long acting
antipsychotic plus an oral antipsychotic among subjects prescribed antipsychotics
1st generation antipsychotic = prescription for a first generation antipsychotic or both a first
and second generation antipsychotic among subjects prescribed antipsychotics
Risperidone prescription = prescription for risperidone among subjects prescribed only 1
antipsychotic. Multiple formulations of the same antipsychotic were counted as a single
antipsychotic.
Olanzapine prescription = prescription for olanzapine among subjects prescribed only 1
antipsychotic. Multiple formulations of the same antipsychotic were counted as a single
antipsychotic.
Antidepressant prescription = prescription for one or more antidepressants.
Caucas = Caucasian
Others = racial categories other than Caucasian and African-American
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AA = African-American
Hisp = Hispanic
Non-Hisp. = not of Hispanic ethnicity
Psych. NOS = psychosis NOS
SCZ = schizophrenia
SCZform = schizophreniform
SCzaff = schizoaffective disorder
Pvt = private
Anxty or Depr. Symps (N-Y) = presence of anxiety or depressive symptoms (not present
versus present)
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Figure 2. Factors Associated with Dosing Patterns For Oral Risperidone or Olanzapine Beta and
Z Scores and 95% Credible Intervals
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Dosing data (expressed as total daily dose) are from prescriptions requiring patients to take a
single antipsychotic solely in an oral formulation
Doses in aqua are from multivariate analyses with selected % of 50% or greater but less than
75% (some evidence of association)
CrI = Credible Interval
Caucas = Caucasian
Others = racial categories other than Caucasian and African-American
AA = African-American
Hisp = Hispanic
Non-Hisp. = not of Hispanic ethnicity
Psych. NOS = psychosis NOS
SCZ = schizophrenia
SCZform = schizophreniform
SCzaff = schizoaffective disorder
Smoking = smoking cigarettes at study entry
Alcohol, Marijuana and Other drugs = use of these substances at study entry
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Author Manuscript

Characteristics of 404 RAISE-ETP Subjects
Mean

95% CI

Median

23.6 years

(23.1, 24.1)

22 years

Number

Percent of subjects

N=293

72.5%

Caucasian

N=218

54%

African-American

N=151

37.4%

American Indian

N=22

5.4%

Asian

N=12

3%

Pacific Islander

N=1

0.2%

Hispanic ethnicity

N=73

18.1%

Had a psychiatric hospitalization prior to enrollment

N=316

78.2%

schizophrenia

N=214

53%

schizophreniform disorder (provisional)

N=57

14.1%

schizophreniform disorder (definite)

N=10

2.5%

schizoaffective disorder, bipolar type

N=24

5.9%

schizoaffective disorder, depressive type

N=57

14.1%

brief psychotic disorder

N=2

0.5%

psychotic disorder NOS

N=40

9.9%

Cigarettes1

N=207

51.4%

Alcohol

N=113

28.0%

Marijuana

N=96

23.8%

other drugs of abuse1

N=10

2.5%

North

N=69

17.1%

South

N=89

22.0%

Mid-West

N=154

38.1%

West

N=92

22.8%

private or private and public

N=82

20.4%

public only

N=127

31.7%

no insurance

N=173

43.1%

Insurance status not known by subject

N=19

4.7%

Age

Male Sex
Racial background

Author Manuscript

Diagnosis at study entry

Currently using substances at study entry

Author Manuscript

Geographic location where receiving treatment

Insurance2

Author Manuscript

1

status not assessed for 1 subject

2

status not assessed for 3 subjects
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Frequency Of Prescription Of Major Medication Classes1

Author Manuscript

Medication class

Number of subjects prescribed a class

Percent of all subjects

No medication

48

11.9%

Only medications for general medical conditions

3

0.7%

Antipsychotics

337

83.4%

Antidepressants

129

31.9%

Mood stabilizer

37

9.2%

Anti-anxiety agent

42

10.4%

Sedative hypnotic

20

5.0%

Opiate analgesics

7

1.7%

Opioid replacement addiction medications

2

0.5%

Stimulants

5

1.2%

Non-stimulant ADHD medication

1

0.2%

α2 adrenergic agonist

3

0.7%

1

subjects could be prescribed more than 1 agent in a class

Author Manuscript
Author Manuscript
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35

30

28

21

12

4

2

2

2

1

1

1

1

aripiprazole

paliperidone

quetiapine

haloperidol

ziprasidone

lurasidone

asenapine

Clozapine

thiothixene

chlorpromazine

fluphenazine

loxapine

perphenazine

N/A = not applicable

51

109

risperidone

olanzapine

Number of subjects
prescribed a
medication (may be
prescribed several
formulations)1

Medication

0.3%

0.3%

0.3%

0.3%

0.7%

0.7%

0.7%

1.3%

4.0%

7%

9.2%

10.0%

11.7%

17.0%

36.3%

Percent

16.5 6
10.0 7

15 6
10 7

309.7 7

300 7

40 7

Oral = 1

Oral = 1

Oral = 1

Oral = 1

Oral = 2

Oral = 2

Oral = 2

Oral = 4

4

40

4

40

15

--7

--7
15

5

250

5

250

10

66.7 7

80 9

10

102.2 9

75

Long Acting = 4
Oral = 12

81.2

10 7

Oral =12

11.3 7

149.5 7

136.5 7

Long Acting = 13
Oral = 28

5.8

6

Oral =17

Oral = 35

Oral = 51

--

75

Long Acting =1

2.9 5

Mean dose
(mg) 2

35

Median dose
(mg) 2

Oral =107

Number prescribed
oral formulation only
or long acting
formulation only

0,885.3

0, 181.4

57.8, 146.7

21.6, 140.9

6.4, 16.1

233.5, 386.0

121.9, 177.1

4.7, 7.0

8.3, 11.7

14.2, 18.7

2.6, 3.2

95% CI

Author Manuscript

Prescriptions For A Single Antipsychotic 300 Subjects

4

40

15

--7

5

200–300

10

40–120 7

40–200 9

50–125

3–30 7

20–800 7

117–234 7

3–9

2–20 7

2.5–40 6

--

0.25–7.0 5

Dose range
(mg) 2

0

N/A

N/A

N/A

18
0

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

226

N/A

85

Number
prescribed higher
than 2009 PORT
dosing for first
episode patients3

--7

0

0

N/A

N/A

19

N/A

3 7,8

17

N/A

0

07

86

N/A

05

Number
prescribed higher
than 2009 PORT
dosing for multiepisode patients

Author Manuscript
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based on 2009 PORT maintenance therapy dose range;

dosing data not available for 3 subjects;

9

8

dosing data not available for 1 subject;

7

dosing data not available for 4 subjects;

for subjects prescribed only long acting medication;

dosing data not available for 2 subjects;

6

5

4

upper daily dose range limit of 15 mg for olanzapine and 5 mg for risperidone based upon 2009 PORT recommendations;

3

for subjects prescribed only oral medications or subjects prescribed only long acting medications; dose is total daily dose for oral medications and total dose per month for long acting medications (e.g. 75
mg for a subject receiving two 37.5 mg injections within a month period);

2

because some subjects were prescribed an oral and a long acting formulation of the same medication, the number of subjects who are prescribed a medication may be larger than the sum of the number
prescribed only oral and only long acting formulations;

Author Manuscript
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